Zobrazeno 1 - 10
of 223
pro vyhledávání: '"Esa, Jantunen"'
Autor:
Aino Rajamaki, Marc Sorigue, Roosa E.I. Prusila, Milla E.L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Taina Turpeenniemi-Hujanen, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. Patients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and third lin
Externí odkaz:
https://doaj.org/article/ce557e7d205e449bb320adff8cfc7f23
Autor:
Elina Kaprio, Roosa Prusila, Susanna Tokola, Milla E. L. Kuusisto, Esa Jantunen, Hanne Kuitunen, Taina Turpeenniemi‐Hujanen, Outi Kuittinen
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Background Rituximab‐based combinations are the standard of care in diffuse large B‐cell lymphoma (DLBCL) and follicular lymphoma (FL). Despite being on market for over 20 years, some of the adverse effects associated with the use of rit
Externí odkaz:
https://doaj.org/article/3ac1de65e388439496cfaa35d413d9a7
Autor:
Minna Harmanen, Tuula Klaavuniemi, Marc Sorigue, Madiha Khan, Roosa Prusila, Esa Kari, Erika Alanne, Aino Rajamäki, Kaisa Sunela, Arja Jukkola, Esa Jantunen, Juan-Manuel Sancho, Sanna Ketola, Hanne Kuitunen, Tuomas Selander, Aino Rönkä, Outi Kuittinen
Publikováno v:
HemaSphere, Vol 7, Iss 10, p e954 (2023)
Externí odkaz:
https://doaj.org/article/aa9ecb854d004f7ca5758be28efefc93
Autor:
Anu Partanen, Antti Turunen, Raija Silvennoinen, Jaakko Valtola, Marja Pyörälä, Timo Siitonen, Anu Sikiö, Mervi Putkonen, Marja Sankelo, Karri Penttilä, Taru Kuittinen, Pentti Mäntymaa, Jukka Pelkonen, Esa Jantunen, Ville Varmavuo
Publikováno v:
Journal of Clinical Apheresis. 38:33-44
Autor:
Thomas Relander, Martin Bjerregård Pedersen, Fredrik Ellin, Grete Fossum Lauritzsen, Esa Jantunen, Hans Hagberg, Harald Holte, Anders Österborg, Peter De Nully Brown, Outi Kuittinen, Martin Erlanson, Bjorn Ostenstad, Unn-Merete Fagerli, Jan Delabie, Christer Sundström, Birgitta Sander, Stephen Hamilton-Dutoit, Mats Ehinger, Knut Liestol, Helle Toldbod, Andrew L. Feldman, Francesco Annibale d'Amore
Publikováno v:
Relander, T, Pedersen, M B, Ellin, F, Lauritzsen, G F, Jantunen, E, Hagberg, H, Holte, H, Österborg, A, Nully Brown, P D, Kuittinen, O, Erlanson, M, Østenstad, B, Fagerli, U-M, Delabie, J, Sundström, C, Sander, B, Hamilton-Dutoit, S J, Ehinger, M, Liestøl, K, Toldbod, H E, Feldman, A L & d'Amore, F A 2022, ' Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial ', Blood, vol. 140, no. Supplement 1, pp. 1479–1480 . https://doi.org/10.1182
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7cbbd991c1c85a79970c806f13128bc
https://pure.au.dk/portal/da/publications/longterm-followup-of-clinical-outcome-determinants-and-correlative-biological-features-from-the-nordic-nlgt01-trial(fad79399-b8e2-47f1-b89e-3d77bc095bda).html
https://pure.au.dk/portal/da/publications/longterm-followup-of-clinical-outcome-determinants-and-correlative-biological-features-from-the-nordic-nlgt01-trial(fad79399-b8e2-47f1-b89e-3d77bc095bda).html
Autor:
Holger W. Auner, Simona Iacobelli, Giulia Sbianchi, Cora Knol-Bout, Didier Blaise, Nigel H. Russell, Jane F. Apperley, David Pohlreich, Paul V. Browne, Guido Kobbe, Cecilia Isaksson, Stig Lenhoff, Christof Scheid, Cyrille Touzeau, Esa Jantunen, Achilles Anagnostopoulos, Ibrahim Yakoub-Agha, Alina Tanase, Nicolaas Schaap, Wieslaw Wiktor-Jedrzejczak, Marta Krejci, Stefan O. Schönland, Curly Morris, Laurent Garderet, Nicolaus Kröger
Publikováno v:
Haematologica, Vol 103, Iss 3 (2018)
Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxic
Externí odkaz:
https://doaj.org/article/f705fa443a5b491689e9661527014272
Autor:
Anu, Partanen, Antti, Turunen, Raija, Silvennoinen, Jaakko, Valtola, Marja, Pyörälä, Timo, Siitonen, Anu, Sikiö, Mervi, Putkonen, Marja, Sankelo, Karri, Penttilä, Taru, Kuittinen, Pentti, Mäntymaa, Jukka, Pelkonen, Esa, Jantunen, Ville, Varmavuo
Publikováno v:
Journal of clinical apheresisREFERENCES.
Prospective data on the impact of CD34This post-hoc study aimed to investigate factors associating with CD34In group C, pegfilgrastim use (P = 0.001), plerixafor use (P = 0.039), and older age ≥ 60 years (P = 0.026) were associated with less loss o
Autor:
Aino Rajamäki, Mika Hujo, Reijo Sund, Roosa E. I. Prusila, Milla E. L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Marc Sorigue, Juan‐Manuel Sancho, Outi Kuittinen, Kaisa Sunela
Publikováno v:
British journal of haematologyREFERENCES. 199(3)
Autor:
Jaakko Valtola, Leena Keskinen, Ville Varmavuo, Esa Jantunen, Jukka Pelkonen, Hanne Kuitunen, Karri Penttilä, Antti Turunen, Marja Pyörälä, Anu Partanen, Taru Kuittinen, Pentti Mäntymaa, Kaija Vasala, Outi Kuittinen
Publikováno v:
Transfusion. 61:516-525
Background Diffuse large B-cell lymphoma (DLBCL) is a common indication for autologous stem cell transplantation (auto-SCT). Study design and methods This prospective noninterventional study aimed to evaluate the impact of mobilization characteristic
Autor:
Esa Jantunen, Elina Kaprio, Milla E.L. Kuusisto, Ville Makkonen, Hanne Kuitunen, Outi Kuittinen, Saila Kauppila, Kirsi-Maria Haapasaari, Taina Turpeenniemi-Hujanen, Peeter Karihtala
Publikováno v:
Annals of Hematology
Although overall survival in diffuse large B cell lymphomas (DLBCL) has improved, central nervous system (CNS) relapse is still a fatal complication of DLBCL. For this reason, CNS prophylaxis is recommended for patients at high risk of CNS disease. H